至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin …

Genes & Diseases. 2019; 
Kuei-LingTungabKai-YuanChenbcMarcosNegretebcTianyiChenbAlexiasSaficeAbed AlhalimAljamaldLingyunSongeGregory E.CrawfordceShengliDingbDavid S.HsucdXilingShenbcf
Products/Services Used Details Operation
Plasmid DNA Preparation All-in-one CRISPR/Cas9-gRNA plasmids (pLentiCRISPR-v2) were purchased from GenScript. Plasmids were extracted using Qiagen Plasmid Maxi Kit. HEK293T cells were transfected with the plasmids to package lentiviruses using TransIT®- LT1 Transfection Reagent (Mirus Bio) according to the manufacturer's instructions. The collected lentiviruses were used to infect organoid cultures to silence genes of interest. Puromycin (2 μg/mL, Thermo Fisher Scientific) was added to the cell culture medium for selection. Get A Quote

摘要

Colorectal cancer is a leading cause of cancer deaths. Most colorectal cancer patients eventually develop chemoresistance to the current standard-of-care therapies. Here, we used patient-derived colorectal cancer organoids to demonstrate that resistant tumor cells undergo significant chromatin changes in response to oxaliplatin treatment. Integrated transcriptomic and chromatin accessibility analyses using ATAC-Seq and RNA-Seq identified a group of genes associated with significantly increased chromatin accessibility and upregulated gene expression. CRISPR/Cas9 silencing of fibroblast growth factor receptor 1 (FGFR1) and oxytocin receptor (OXTR) helped overcome oxaliplatin resistance. Similarly, treatment with ... More

关键词

Chromatin accessibilityDrug screeningPatient-derived organoidsPersonalized medicineTarget discovery